Introduction to Competitive ELISA
Competitive ELISA is a laboratory technique to detect and quantify specific proteins or molecules. It involves a competition between the target molecule and a labeled analog for binding to immobilized antibodies. The signal intensity is inversely proportional to the analyte concentration, enabling quantitative measurements.
In a competitive ELISA, the target molecule of interest, known as the analyte, competes with a labeled or enzyme-conjugated form of the same molecule (analyte analog) for binding to a limited amount of specific antibodies immobilized on a solid surface, such as a microplate. The analyte analog is typically labeled with an enzyme, such as horseradish peroxidase or alkaline phosphatase, which can generate a detectable signal.
Exploiting Opportunities and Future Prospects of Competitive ELISA Market
During the early COVID-19 pandemic, the absence of specific diagnostic tests posed a challenge. However, this created a lucrative market opportunity for diagnostic manufacturers to introduce COVID-19 diagnostic kits. Leading players and startups worldwide capitalized on this gap, introducing COVID-19 diagnostic kits globally.
The Department of Science and Technology highlights ELISA tests' significance as routine serosurvey tools for infection detection and as quantifiers of antibodies. This enables crucial insights into antibody dynamics, vaccine efficacy, and seroconversion responses, making ELISA a vital component in future vaccination programs. This scenario presents a comprehensive analysis of the impact of COVID-19 on the Competitive ELISA Market.
Market Drivers and Impact Analysis of Competitive ELISA Market
Several key factors influence the Competitive ELISA Market. The increasing prevalence of chronic and infectious diseases, such as the COVID-19 outbreak, drives the demand for accurate diagnostic tools like ELISA tests. The rising geriatric population, augmented R&D investment in ELISA development kits, and advancements in healthcare infrastructure also contribute to market growth.
Additionally, expanding the biotechnology and biopharmaceutical industries further propels the market. The FDA's Emergency Authorization Use for various ELISA assays, including those for SARS-CoV-2 antibody detection, supports vaccine development and public health surveillance, enhancing the market's prospects.
Conclusion
The Competitive ELISA Market has witnessed significant growth and opportunities, particularly during the COVID-19 pandemic. The unavailability of specific diagnostic tests initially created a market void promptly filled by manufacturers introducing COVID-19 diagnostic kits. ELISA tests have become valuable for serosurveys, quantifying antibodies, and understanding vaccine efficacy.
Author's Detail
Surabhi Bhaiyya LinkedInProfile
Surabhi Bhaiyya is an experienced market researcher focused on the Pharma & Healthcare industry. With over 7+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
Author's Detail:
Surabhi Bhaiyya /
LinkedIn
Senior Research Analyst at Cognitive Market Research
Surabhi Bhaiyya is an experienced market researcher focused on the Pharma & Healthcare industry. With over 7+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
